Harbin Medisan Pharmaceutical Co., Ltd.
Symbol: 002900.SZ
SHZ
10.31
CNYTržní cena dnes
62.4601
Poměr P/E
1.8348
Poměr PEG
3.19B
MRK Cap
- 0.01%
Výnos DIV
Harbin Medisan Pharmaceutical Co., Ltd. (002900-SZ) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1048.9 | 1293.9 | 1111.5 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 57.8 | 91.3 | 581.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 150.6 | 164.1 | 149.6 | ||||||||||||
balance-sheet.row.inventory | 0 | 208.8 | 161.2 | 156.5 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 28.2 | 4.5 | 9.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1436.4 | 1623.7 | 1427.2 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1081.6 | 882.4 | 925.3 | ||||||||||||
balance-sheet.row.goodwill | 0 | 1.3 | 0.5 | 9.4 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 141.2 | 71.7 | 62.5 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 142.5 | 72.2 | 71.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 651.2 | 555.6 | 22.8 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 23.1 | 23.8 | 25.8 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 108.1 | 119.1 | 592.4 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 2006.5 | 1653.1 | 1638.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 182.1 | 120.8 | 105.2 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 480.2 | 233.8 | 274.8 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 3.1 | 12.2 | 11.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 238.2 | 422.9 | 212.9 | ||||||||||||
Deferred Revenue Non Current | 0 | 79 | 83.9 | 89 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 7.9 | 188.3 | 2.5 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 449.7 | 627.1 | 412.4 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 8.3 | 5.1 | 8 | ||||||||||||
balance-sheet.row.total-liab | 0 | 1294.8 | 1224.8 | 949 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 316.4 | 316.6 | 316.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 612.9 | 570.7 | 639.6 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 162.5 | 192.3 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1211.2 | 990.9 | 952.9 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2140.5 | 2040.7 | 2101.4 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 7.7 | 11.3 | 15 | ||||||||||||
balance-sheet.row.total-equity | 0 | 2148.2 | 2052 | 2116.5 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 709 | 646.9 | 604.5 | ||||||||||||
balance-sheet.row.total-debt | 0 | 718.4 | 656.7 | 487.7 | ||||||||||||
balance-sheet.row.net-debt | 0 | -272.8 | -545.9 | -42.2 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 26.5 | 349.7 | 26.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 106.6 | 99.1 | 79.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | -11.7 | -95 | 1.4 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 49.5 | 107.4 | -160.1 | |||||||||||
cash-flows.row.account-receivables | 0 | -10 | 49.6 | 49.1 | |||||||||||
cash-flows.row.inventory | 0 | 0.6 | 26.5 | 31.9 | |||||||||||
cash-flows.row.account-payables | 0 | 47.2 | -63.7 | -239.6 | |||||||||||
cash-flows.row.other-working-capital | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | -37.9 | -568.8 | 49 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0.3 | 11.6 | 146.4 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -72 | -1113.7 | -1091 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 580.2 | 901.9 | 1437.6 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -4.1 | -145.9 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 419.3 | -278.2 | 201.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -270.2 | -269.5 | -230 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -109.3 | -34.3 | -95.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 272.4 | 260.1 | 323.2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -107.1 | -43.7 | -2.6 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 456.8 | -334.5 | 194.2 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 782.3 | 325.5 | 660 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 325.5 | 660 | 465.7 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 144.6 | -12.5 | -4.5 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 55.4 | -86.5 | -150.4 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1186.8 | 1028.4 | 945.8 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 476.4 | 365.6 | 309.4 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 710.4 | 662.8 | 636.4 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 693.4 | 679.6 | 765.2 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1169.7 | 1045.1 | 1074.6 | ||||||||||||
income-statement-row.row.interest-income | 0 | 27.9 | 28.3 | 11.8 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 108.7 | 106.6 | 122.9 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 79 | 57.6 | 454.8 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 81.4 | 40.1 | 452.9 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 11.3 | 13.6 | 103.2 | ||||||||||||
income-statement-row.row.net-income | 0 | 73.7 | 30.2 | 351 |
Často kladené otázky
Co je Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) celková aktiva?
Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) celková aktiva jsou 3442984089.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.582.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -1.022.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.049.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.026.
Co je Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 73663110.000.
Jaký je celkový dluh podniku?
Celkový dluh je 718376453.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 693357200.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.